GRAIL Galleri Multi-Cancer Blood Test Cuts Stage IV Diagnoses in NHS Trial

Originally surfaced May 31, 2026.

At the 2026 American Society of Clinical Oncology Annual Meeting, GRAIL presented full results from the NHS-Galleri trial, the largest randomized study to date of a multi-cancer early detection blood test. The trial enrolled more than 142,000 participants aged 50 to 77 in England and compared annual screening with the Galleri test against usual NHS care.

The headline is genuinely mixed. The trial did not meet its primary endpoint, which was a reduction in the combined number of stage III and stage IV cancers across the screening population. But it did show a substantial reduction in stage IV diagnoses specifically, with more than 20 percent fewer advanced cancers found in the second and third screening rounds among people who received the test. Adding Galleri to standard-of-care screening also raised the overall cancer detection rate roughly fourfold.

For people thinking about cancer screening blood tests, this trial deserves to be understood on its own terms rather than packaged as either a triumph or a flop.

What the test does and does not do

Galleri is a multi-cancer early detection test, often shortened to MCED. It uses cell-free DNA in a blood sample to look for cancer-associated methylation patterns and to predict the likely tissue of origin if a signal is detected. It screens for signals from more than 50 cancer types, many of which have no recommended screening test of their own.

MCED tests are not a replacement for the established single-cancer screening programs people already know. They are not a replacement for mammography, colonoscopy, low-dose CT for high-risk smokers, or cervical screening. The NHS-Galleri investigators did not test Galleri as a replacement. They tested it as an addition.

What the trial actually showed

The primary endpoint, combined stage III and IV cancer reduction, did not reach statistical significance. That is the hard fact behind the mixed headlines.

The secondary findings are still meaningful:

• A reduction of more than 20 percent in stage IV diagnoses in the second and third annual screening rounds
• An approximately fourfold increase in cancer detection rate when Galleri was added to standard NHS screening
• Detection signals across many cancers that currently lack any organized screening program

The stage IV reduction matters because stage IV is where survival drops sharply for most cancers. Catching cancer one stage earlier, especially for cancers that do not currently have a screening test, is the central public-health argument for MCED.

What this trial cannot answer yet

The NHS-Galleri trial was not designed to prove a mortality benefit, and it does not. Whether earlier detection translates into longer survival, particularly for tumor types where biology drives outcomes more than stage at diagnosis, is the next question. That is the bar most cancer-screening programs are eventually held to.

False positives, follow-up workup burden, and overdiagnosis all remain open questions for MCED tests broadly. Those are not unique to Galleri, but they are worth keeping in mind when reading the press coverage.

What to do with this if you are not in a trial

Galleri is not currently FDA approved, and Medicare coverage for MCED tests in the U.S. depends on the framework set up by the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act passed earlier in 2026, which paves the way for coverage once FDA approval lands. Until then, MCED tests in the U.S. are available as laboratory-developed tests and are typically self-pay.

For anyone evaluating cancer screening today without an MCED test on the table, the more grounded options remain the single-cancer screening tests that already have established evidence: colonoscopy or stool-based testing for colorectal cancer, mammography for breast cancer, low-dose CT for lung cancer in eligible smokers, cervical screening for cervical cancer, and a thoughtful conversation about PSA testing for men in the relevant age window. Tumor markers used in already-diagnosed disease, such as CEA, CA-125, CA 19-9, and AFP, are not screening tools for asymptomatic average-risk adults.

This article is editorial commentary and is not medical advice. Cancer screening decisions should be made with a clinician who knows your personal and family history.

Update: August 14, 2026

The full prespecified endpoint numbers make the mixed result more precise. Across the 12 prespecified cancers and all three screening rounds, combined Stage III/IV diagnoses were 706 in the Galleri arm and 688 in the control arm, for an incidence rate ratio of 1.03 (95% CI, 0.92 to 1.14; p=0.6324). That primary endpoint was not met.

Stage IV alone moved in the other direction: 342 diagnoses in the Galleri arm versus 397 in the control arm, an overall incidence rate ratio of 0.86 (95% CI, 0.744 to 0.998), equal to a 14% reduction across the three rounds. The result does not erase the missed primary endpoint or establish a mortality benefit. It does sharpen the distinction between no reduction in combined Stage III/IV disease and fewer Stage IV diagnoses as a secondary endpoint.

What's new: August 28, 2026

The FDA has scheduled a public meeting of its Molecular and Clinical Genetics Panel for September 23, 2026. The panel will discuss, make recommendations, and vote on GRAIL's premarket approval application for Galleri. The notice marks a regulatory review milestone, not an approval decision.